{"id":"tnf-antagonist","safety":{"commonSideEffects":[{"rate":null,"effect":"Increased infection risk (including tuberculosis)"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Demyelinating disease (rare)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNF antagonists inhibit TNF-α signaling by either binding directly to TNF-α (monoclonal antibodies) or acting as TNF receptors that sequester TNF (fusion proteins). This reduces the activation of immune cells and inflammatory cascades, thereby suppressing pathological inflammation in autoimmune and inflammatory conditions.","oneSentence":"TNF antagonists block tumor necrosis factor (TNF), a key inflammatory cytokine that drives immune-mediated inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:38:52.696Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Rheumatoid arthritis"},{"name":"Crohn's disease"},{"name":"Ulcerative colitis"},{"name":"Ankylosing spondylitis"},{"name":"Psoriasis"},{"name":"Psoriatic arthritis"}]},"trialDetails":[{"nctId":"NCT07477795","phase":"PHASE2","title":"Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients","status":"NOT_YET_RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2026-04-01","conditions":"Takayasu Arteritis, Large Vessel Vasculitis","enrollment":52},{"nctId":"NCT07491913","phase":"NA","title":"Biologic Treatment Withdrawal in Takayasu Arteritis Patients in Sustained Remission","status":"RECRUITING","sponsor":"Marmara University","startDate":"2025-06-15","conditions":"Takayasu Arteritis","enrollment":40},{"nctId":"NCT06654882","phase":"PHASE3","title":"Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis","status":"RECRUITING","sponsor":"Duke University","startDate":"2026-01-09","conditions":"Polyarticular Course Juvenile Idiopathic Arthritis (JIA)","enrollment":400},{"nctId":"NCT07453628","phase":"","title":"Association of Erectile Dysfunction With Neuropathic Pain, Disease Activity, and Functional Status in Male Patients With Axial Spondyloarthritis: A Cross-Sectional Observational Study","status":"COMPLETED","sponsor":"Altuğ Güner","startDate":"2021-02-03","conditions":"Ankylosing Spondylitis, Sexual Dysfunction","enrollment":90},{"nctId":"NCT00385086","phase":"PHASE3","title":"Lumbar Spinal Fibrosis and TNF Alpha Inhibition","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2007-02","conditions":"Post Operative Sciatica by Lumbar Spinal Fibrosis","enrollment":38},{"nctId":"NCT06905288","phase":"","title":"Real-world Study on Secukinumab Effectiveness in Biologic-naïve Ankylosing Spondylitis (AS) Patients in Korea.","status":"RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-04-02","conditions":"Ankylosing Spondylitis","enrollment":70},{"nctId":"NCT06712628","phase":"","title":"A Comparison Study of Persistence of UPadacitinib vs. TNF-inhibitoRs In a German Real-world SettING","status":"RECRUITING","sponsor":"AbbVie","startDate":"2024-11-07","conditions":"Moderate to Severe Rheumatoid Arthritis","enrollment":678},{"nctId":"NCT05782335","phase":"","title":"Analysis of T and B Cell Repertoire Changes in Response to Orencia® (Abatacept) in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"Hospital for Special Surgery, New York","startDate":"2022-11-01","conditions":"Rheumatoid Arthritis","enrollment":72},{"nctId":"NCT06440629","phase":"PHASE4","title":"Effect of Proactive Therapeutic Drug Monitoring on Maintenance of Sustained Disease Control in Adults With Rheumatoid Arthritis on a Subcutaneous TNF Inhibitor: The Rheumatoid Arthritis Therapeutic DRUg Monitoring Trial (RA-DRUM)","status":"RECRUITING","sponsor":"Diakonhjemmet Hospital","startDate":"2024-08-20","conditions":"Rheumatoid Arthritis","enrollment":350},{"nctId":"NCT07386587","phase":"PHASE3","title":"Methotrexate Alone vs Methotrexate + Etanercept for Minimal/Low Disease Activity in Juvenile Idiopathic Arthritis","status":"ENROLLING_BY_INVITATION","sponsor":"University of Child Health Sciences and Children's Hospital, Lahore","startDate":"2026-01-27","conditions":"Juvenile Idiopathic Arthritis","enrollment":60},{"nctId":"NCT02714881","phase":"","title":"Lipids, Inflammation, and CV Risk in RA","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-10-17","conditions":"Rheumatoid Arthritis, Cardiovascular Disease","enrollment":74},{"nctId":"NCT07117344","phase":"","title":"Biomarkers in Ankylosing Spondylitis","status":"RECRUITING","sponsor":"Kirsehir Ahi Evran Universitesi","startDate":"2026-01-15","conditions":"Ankylosing Spondylitis (AS) / Radiographic Axial SpA (r-axSpA)","enrollment":160},{"nctId":"NCT05814627","phase":"PHASE3","title":"Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis","status":"ACTIVE_NOT_RECRUITING","sponsor":"AbbVie","startDate":"2023-06-15","conditions":"Rheumatoid Arthritis","enrollment":487},{"nctId":"NCT04799496","phase":"","title":"A Study of Kynteles Injection (Vedolizumab) in Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease or Chronic Pouchitis","status":"COMPLETED","sponsor":"Takeda","startDate":"2020-06-10","conditions":"Inflammatory Bowel Diseases, Colitis, Ulcerative, Crohn Disease","enrollment":688},{"nctId":"NCT05590455","phase":"PHASE2","title":"Tnf Inhibitors to Reduce Mortality in HIV-1 Infected PAtients With Tuberculosis meNIngitis","status":"RECRUITING","sponsor":"ANRS, Emerging Infectious Diseases","startDate":"2023-04-11","conditions":"Tuberculous Meningitis, HIV I Infection","enrollment":130},{"nctId":"NCT03739853","phase":"PHASE4","title":"Severe Psoriatic Arthritis - Early intervEntion to Control Disease: the SPEED Trial","status":"COMPLETED","sponsor":"University of Oxford","startDate":"2019-05-14","conditions":"Psoriatic Arthritis","enrollment":192},{"nctId":"NCT01022749","phase":"PHASE3","title":"Efficacy Safety Study of Flu Vaccine in Immunodepression Patients","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-09","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":228},{"nctId":"NCT03123120","phase":"PHASE2","title":"A Study in Patients With Mild or Moderate Ulcerative Colitis Who Take a TNF Inhibitor. The Study Investigates Whether Bowel Inflammation Improves When Patients Take BI 655130 in Addition to Their Current Therapy","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2017-06-07","conditions":"Colitis, Ulcerative","enrollment":22},{"nctId":"NCT05428345","phase":"","title":"A Study of Vedolizumab SC Given to Adults With Moderate to Severe Ulcerative Colitis or Crohn's Disease in South Korea","status":"RECRUITING","sponsor":"Takeda","startDate":"2023-09-25","conditions":"Ulcerative Colitis, Crohn's Disease, Inflammatory Bowel Disease (IBD)","enrollment":600},{"nctId":"NCT05428488","phase":"PHASE3","title":"Efficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis","status":"RECRUITING","sponsor":"University Hospital, Montpellier","startDate":"2022-11-28","conditions":"Rheumatoid Arthritis","enrollment":220},{"nctId":"NCT07181694","phase":"PHASE1","title":"A Study of Pharmacokinetics, Safety, and Immunogenicity of BCD-057 100 mg/mL, BCD-057 50 mg/mL, and Humira 100 mg/mL in Healthy Subjects","status":"RECRUITING","sponsor":"Biocad","startDate":"2025-03-12","conditions":"Healthy Adult Male","enrollment":444},{"nctId":"NCT07198113","phase":"","title":"COMPARE - Pediatric Inflammatory Bowel Disease (PIBD)","status":"NOT_YET_RECRUITING","sponsor":"University of North Carolina, Chapel Hill","startDate":"2025-11-01","conditions":"Ulcerative Colitis, Pediatric, Inflammatory Bowel Diseases, Crohn Disease","enrollment":1100},{"nctId":"NCT07176754","phase":"NA","title":"TNF-α Antagonists Mitigate Systemic Inflammatory Response After Cardiac Arrest.","status":"NOT_YET_RECRUITING","sponsor":"Peking University Third Hospital","startDate":"2025-10-01","conditions":"Cardiac Arrest (CA), Post Cardiac Arrest Syndrome","enrollment":208},{"nctId":"NCT07166315","phase":"","title":"Treatment Effectiveness in People With axSpA or PsA Starting Treatment With Bimekizumab, Risankizumab, Guselkumab, Upadacitinib, or a TNF Inhibitor","status":"RECRUITING","sponsor":"Adelphi Real World","startDate":"2025-07-07","conditions":"Axial Spondylarthritis (axSpA), Psoriatic Arthritis (PsA)","enrollment":700},{"nctId":"NCT07138898","phase":"PHASE2","title":"Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty","status":"NOT_YET_RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-09","conditions":"Rheumatic Disease","enrollment":80},{"nctId":"NCT07021495","phase":"","title":"SKIN Disease Profiling by an Exploratory, pRospective, Biomarker Study in dermatoloGY Practice (SKINERGY)","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2025-07-29","conditions":"Chronic Spontaneous Urticaria (CSU), Hidradenitis Suppurativa (HS), Psoriasis (PsO)","enrollment":840},{"nctId":"NCT06418529","phase":"","title":"A Study to Understand How Effective is Tofacitinib When Compared to Other Advanced Treatments in Patients With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-05-15","conditions":"Rheumatoid Arthritis","enrollment":21340},{"nctId":"NCT03915964","phase":"PHASE4","title":"A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-04-25","conditions":"Rheumatoid Arthritis","enrollment":2663},{"nctId":"NCT03358693","phase":"","title":"Molecular Signatures in Inflammatory Skin Disease","status":"RECRUITING","sponsor":"Prof. Dr. Stephan Weidinger","startDate":"2017-01-20","conditions":"Atopic Dermatitis, Psoriasis","enrollment":300},{"nctId":"NCT04086745","phase":"PHASE4","title":"A Study of Baricitinib in Participants With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2020-02-14","conditions":"Rheumatoid Arthritis","enrollment":1317},{"nctId":"NCT00463580","phase":"PHASE4","title":"A Study of Infliximab for Treatment Resistant Major Depression","status":"COMPLETED","sponsor":"Emory University","startDate":"2008-12","conditions":"Depression","enrollment":60},{"nctId":"NCT07041112","phase":"","title":"Ten-Year Biologic Drug Survival in Psoriasis: Role of Genetic and Cardiometabolic Predictors","status":"COMPLETED","sponsor":"Juan Ruano Ruiz","startDate":"2012-01-01","conditions":"Psoriasis, Psoriatic Arthritis (PsA), Cardiovascular Risk Factors","enrollment":1000},{"nctId":"NCT05080218","phase":"PHASE4","title":"COVID-19 VaccinE Response in Rheumatology Patients","status":"COMPLETED","sponsor":"Jeffrey Curtis","startDate":"2021-11-15","conditions":"Rheumatoid Arthritis, Psoriatic Arthritis, Spondylarthritis","enrollment":841},{"nctId":"NCT06281106","phase":"PHASE2, PHASE3","title":"TYK2 Inhibition in Paradoxical Psoriasis","status":"TERMINATED","sponsor":"Prof Curdin Conrad","startDate":"2024-06-20","conditions":"Psoriasis","enrollment":2},{"nctId":"NCT06653634","phase":"PHASE4","title":"Optimizing Treatment for Patients With Juvenile Idiopathic Arthritis in Sustained Remission: The MOVE-JIA Trial","status":"RECRUITING","sponsor":"Oslo University Hospital","startDate":"2024-10-24","conditions":"Juvenile Idiopathic Arthritis","enrollment":150},{"nctId":"NCT06856447","phase":"PHASE1","title":"The Role of Coenzyme Q10 in the Prophylaxis of Oxaliplatin Induced Peripheral Neuropathy in Patients With Colorectal Cancer","status":"RECRUITING","sponsor":"toqa saad mohammed mohammed","startDate":"2024-06-01","conditions":"Colorectal Cancer","enrollment":22},{"nctId":"NCT04254627","phase":"PHASE1","title":"TNF and Glucocorticoid Antagonist for GWI Associated Multi-symptom Disease Homeostasis Reset","status":"ACTIVE_NOT_RECRUITING","sponsor":"Nova Southeastern University","startDate":"2021-09-24","conditions":"Gulf War Illness","enrollment":20},{"nctId":"NCT01086059","phase":"","title":"OTIS Humira Pregnancy Registry","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2003-11","conditions":"Crohn's Disease, Rheumatoid Arthritis","enrollment":944},{"nctId":"NCT05350644","phase":"","title":"Inflammatory Bowel Disease(IBD), Treatment Response","status":"TERMINATED","sponsor":"University of Southern Denmark","startDate":"2022-02-08","conditions":"Inflammatory Bowel Diseases, Ulcerative Colitis, Crohn Disease","enrollment":2},{"nctId":"NCT03445845","phase":"PHASE4","title":"Rotation or Change of Biotherapy After TNF Blocker Treatment Failure for Axial Spondyloarthritis","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2018-12-14","conditions":"Axial Spondyloarthritis","enrollment":300},{"nctId":"NCT04347798","phase":"","title":"IMPACT: IMPact of Antimalarials on Covid-19 Infections in RAPPORT","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2020-11-01","conditions":"Covid-19 Infection, Rheumatoid Arthritis, Psoriatic Arthritis","enrollment":773},{"nctId":"NCT06601595","phase":"","title":"Prevelance of Axial Spondylosis Arthritis in Inflammatory Bowel Disease and Its RESPONSE to Tumour Necrosis Factor (TNF) Inhibitors Treatment in Assiut University Hospital","status":"NOT_YET_RECRUITING","sponsor":"Mohamed Nasr","startDate":"2024-10","conditions":"Inflammatory Bowel Disease (IBD), Spondylarthropathies, TNF-alpha Inhibitors","enrollment":100},{"nctId":"NCT06563635","phase":"","title":"Frequency of Tuberculosis in Psoriasis Patients","status":"COMPLETED","sponsor":"Bezmialem Vakif University","startDate":"2023-05-01","conditions":"Psoriasis Vulgaris, Tuberculosis","enrollment":719},{"nctId":"NCT04725422","phase":"","title":"CHronic Nonbacterial Osteomyelitis International Registry","status":"RECRUITING","sponsor":"Seattle Children's Hospital","startDate":"2018-08-01","conditions":"Chronic Nonbacterial Osteomyelitis, Chronic Recurrent Multifocal Osteomyelitis","enrollment":2000},{"nctId":"NCT03182426","phase":"PHASE1, PHASE2","title":"Stem Cell Mobilization (Plerixafor) and Immunologic Reset in Type 1 Diabetes (T1DM)","status":"COMPLETED","sponsor":"University of Alberta","startDate":"2017-08-15","conditions":"Diabetes Mellitus, Type 1","enrollment":22},{"nctId":"NCT01242488","phase":"PHASE2","title":"Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy","status":"COMPLETED","sponsor":"UCB Pharma","startDate":"2010-11","conditions":"Rheumatoid Arthritis","enrollment":221},{"nctId":"NCT02450513","phase":"","title":"Adalimumab Trough Concentrations in Crohn's Disease: A Pilot Pharmacokinetic Study","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2012-03","conditions":"Crohn's Disease","enrollment":30},{"nctId":"NCT03652961","phase":"PHASE4","title":"Rheumatoid Arthritis Memory B Cells and Abatacept","status":"COMPLETED","sponsor":"NYU Langone Health","startDate":"2019-06-02","conditions":"Rheumatoid Arthritis","enrollment":25},{"nctId":"NCT04731831","phase":"","title":"Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.","status":"RECRUITING","sponsor":"Aalborg University Hospital","startDate":"2020-08-01","conditions":"Arthritis, Rheumatoid, Arthritis, Psoriatic, Spondylitis, Ankylosing","enrollment":120},{"nctId":"NCT06400589","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Tanfanercept (HL036) in Dry Eye Disease","status":"SUSPENDED","sponsor":"HanAll BioPharma Co., Ltd.","startDate":"2024-05-01","conditions":"Dry Eye","enrollment":750},{"nctId":"NCT04721821","phase":"","title":"Comparative Effectiveness Of Tumor Necrosis Factor Inhibitors And Tofacitinib Use In Earlier Lines Of Therapy And Use As Monotherapy.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-01-22","conditions":"Arthritis Rheumatoid","enrollment":7807},{"nctId":"NCT06299631","phase":"","title":"Endoscopic Relapse Risks Evaluation After Ileocolic Resection for Crohn's Disease","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2015-01","conditions":"Crohn's Disease","enrollment":133},{"nctId":"NCT03839862","phase":"","title":"Faecal Analyses in Spondyloarthritis Therapy","status":"RECRUITING","sponsor":"Region Skane","startDate":"2019-01-01","conditions":"Spondyloarthropathies, Ankylosing Spondylitis","enrollment":50},{"nctId":"NCT05447182","phase":"","title":"People-Powered Medicine (PPM): Rheumatoid Arthritis Non-responders to Biologic Therapies (RANT)","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-07-06","conditions":"Rheumatoid Arthritis","enrollment":300},{"nctId":"NCT05115903","phase":"PHASE4","title":"Biologic Tapering Study of TNF Inhibitors in Axial Spondyloarthritis","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-12-01","conditions":"Axial Spondyloarthritis","enrollment":15},{"nctId":"NCT06177405","phase":"","title":"Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors","status":"COMPLETED","sponsor":"Institute of Biomedical Chemistry, Russia","startDate":"2021-01-15","conditions":"Rheumatoid Arthritis","enrollment":50},{"nctId":"NCT05930613","phase":"PHASE3","title":"Certolizumab in Recurrent Implantation Failure (RIF)","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-11-30","conditions":"Recurrent Unexplained Implantation Failure","enrollment":161},{"nctId":"NCT05702879","phase":"","title":"Combined Microbiota and Metabolic Signature in Ulcerative Colitis Predicts Anti-Inflammatory Therapy Success","status":"UNKNOWN","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-09-06","conditions":"Ulcerative Colitis","enrollment":240},{"nctId":"NCT06109961","phase":"PHASE1, PHASE2","title":"Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot Study","status":"NOT_YET_RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2024-01","conditions":"Inflammatory Bowel Disease (IBD)","enrollment":40},{"nctId":"NCT00116272","phase":"","title":"Organization of Teratology Information Services (OTIS) Autoimmune Diseases in Pregnancy Project","status":"COMPLETED","sponsor":"Amgen","startDate":"2005-04","conditions":"Pregnancy","enrollment":830},{"nctId":"NCT03293784","phase":"PHASE1","title":"TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanoma","status":"COMPLETED","sponsor":"Institut Claudius Regaud","startDate":"2017-10-16","conditions":"Melanoma","enrollment":33},{"nctId":"NCT04255134","phase":"PHASE4","title":"Biologics for Rheumatoid Arthritis Pain (BIORA-PAIN)","status":"COMPLETED","sponsor":"St George's, University of London","startDate":"2020-09-07","conditions":"Rheumatoid Arthritis","enrollment":18},{"nctId":"NCT03619876","phase":"PHASE4","title":"Effects of Abatacept on Myocarditis in Rheumatoid Arthritis","status":"TERMINATED","sponsor":"Columbia University","startDate":"2019-07-10","conditions":"Rheumatoid Arthritis, Myocardial Inflammation","enrollment":11},{"nctId":"NCT05767814","phase":"","title":"Optimization of Psoriatic and Seronegative Rheumatoid Arthritis Patients Selection and Treatment Outcomes of Biologic Therapies.","status":"UNKNOWN","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2019-10-03","conditions":"Psoriatic Arthritis, Rheumatoid Arthritis","enrollment":135},{"nctId":"NCT05182203","phase":"","title":"Safety and Retention Rate of the JAK and TNF Inhibitors in Rheumatoid Arthritis: a Real-life Experience","status":"COMPLETED","sponsor":"Tuen Mun Hospital","startDate":"2022-03-01","conditions":"Rheumatoid Arthritis, Drug Use","enrollment":1732},{"nctId":"NCT05651373","phase":"","title":"The Clinical Features and Pregnancy Outcomes of RA Patients","status":"UNKNOWN","sponsor":"Qilu Hospital of Shandong University","startDate":"2021-07-30","conditions":"Rheumatoid Arthritis, Pregnancy Related","enrollment":100},{"nctId":"NCT02374021","phase":"PHASE4","title":"Treatments Against RA and Effect on FDG-PET/CT","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2016-07","conditions":"Arthritis, Rheumatoid","enrollment":159},{"nctId":"NCT03589833","phase":"PHASE4","title":"Effectiveness and Safety of Yisaipu Combined With Tripterygium Wilfordii for Active RA","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2019-05-14","conditions":"Arthritis, Rheumatoid","enrollment":504},{"nctId":"NCT05567380","phase":"","title":"Comparative Study of Janus Kinase (JAK) Inhibitors Vs Tumor Necrosis Factor (TNF) Inhibitors in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Sohag University","startDate":"2022-10","conditions":"Rheumatoid Arthritis","enrollment":150},{"nctId":"NCT03351647","phase":"","title":"Predictive Factors of Clinical Response to Ustekinumab in Active Crohn's Disease","status":"COMPLETED","sponsor":"Hospices Civils de Lyon","startDate":"2018-02-14","conditions":"Crohn Disease","enrollment":18},{"nctId":"NCT03331393","phase":"","title":"The Value of Orencia in Rapidly Progressing Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-16","conditions":"Rheumatoid Arthritis","enrollment":265},{"nctId":"NCT04798287","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-03-10","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT03033095","phase":"NA","title":"Prediction of the Answer to the Treatment by Biotherapies for Naive Spondyloarthritis by Combinatorial Analysis of Serum Biomarkers","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2016-07","conditions":"Spondylitis, Ankylosing","enrollment":50},{"nctId":"NCT05405465","phase":"","title":"Effectiveness of Golimumab in Patients With Ulcerative Colitis: Results of a Real-life Study in Switzerland","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2018-01-01","conditions":"Ulcerative Colitis, Flare Up, Symptom","enrollment":103},{"nctId":"NCT04399382","phase":"","title":"A Clinical Study to Evaluate the Efficacy of Biologics in SpA","status":"UNKNOWN","sponsor":"The University of Hong Kong-Shenzhen Hospital","startDate":"2022-01-12","conditions":"Spondyloarthritis (SpA)","enrollment":40},{"nctId":"NCT03419143","phase":"","title":"Safety and Effectiveness of Abatacept in Psoriatic Arthritis Participants","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2018-03-02","conditions":"Psoriatic Arthritis (PsA)","enrollment":190},{"nctId":"NCT05379049","phase":"","title":"Therapeutic Response to Tumor Necrosis Factor-alpha (TNF-alpha) Antagonists in Rheumatoid Arthritis.","status":"UNKNOWN","sponsor":"University of Sulaimani","startDate":"2022-03-01","conditions":"Rheumatoid Arthritis, Inflammatory Arthritis, Ankylosing Spondylitis","enrollment":80},{"nctId":"NCT03449758","phase":"PHASE4","title":"Effect of Sarilumab on Patient-reported Outcomes in Patients With Active Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-03-05","conditions":"Rheumatoid Arthritis","enrollment":84},{"nctId":"NCT01881308","phase":"PHASE4","title":"Assessing Withdrawal of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Diakonhjemmet Hospital","startDate":"2013-06-17","conditions":"Rheumatoid Arthritis","enrollment":320},{"nctId":"NCT04370236","phase":"PHASE2, PHASE3","title":"INB03 for the Treatment of Pulmonary Complications From COVID-19","status":"TERMINATED","sponsor":"Inmune Bio, Inc.","startDate":"2020-10-21","conditions":"COVID-19","enrollment":79},{"nctId":"NCT03663829","phase":"","title":"Impact of Anti-citrullinated Protein Antibody Status on Treatment Response and Treatment Persistence in Participants With Rheumatoid Arthritis (RA) Who Are Treated With Abatacept or Tumor Necrosis Factor Inhibitors in Australia","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-10-04","conditions":"Rheumatoid Arthritis","enrollment":2052},{"nctId":"NCT04772248","phase":"","title":"Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)- Cardiovascular Endpoints","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-22","conditions":"Rheumatoid Arthritis","enrollment":105711},{"nctId":"NCT05164198","phase":"PHASE4","title":"REduCed Dose of TNFi in Patients With Ankylosing SpondyliTis (RECAST)","status":"UNKNOWN","sponsor":"Hanyang University Seoul Hospital","startDate":"2022-01-15","conditions":"Ankylosing Spondylitis, Axial Spondyloarthritis","enrollment":448},{"nctId":"NCT05153200","phase":"PHASE4","title":"Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.","status":"UNKNOWN","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-01","conditions":"Rheumatoid Arthritis","enrollment":40},{"nctId":"NCT02136069","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab to Infliximab in Participants With Moderate to Severe Ulcerative Colitis Who Are Naïve to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-12-24","conditions":"Ulcerative Colitis","enrollment":397},{"nctId":"NCT04729296","phase":"PHASE2","title":"Anti-TNFα to Delay or Prevent Progression to Stage 3 T1D","status":"WITHDRAWN","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2021-07-01","conditions":"Diabetes Mellitus, Type 1","enrollment":""},{"nctId":"NCT04529902","phase":"","title":"Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept","status":"COMPLETED","sponsor":"Brigham and Women's Hospital","startDate":"2020-08-17","conditions":"Rheumatoid Arthritis","enrollment":63013},{"nctId":"NCT05119452","phase":"NA","title":"Screening for Flare After b/tsDMARD Discontinuation in Rheumatoid Arthritis","status":"UNKNOWN","sponsor":"Medical University of Vienna","startDate":"2022-03","conditions":"Rheumatoid Arthritis","enrollment":85},{"nctId":"NCT02165215","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-08-12","conditions":"Colitis, Ulcerative","enrollment":359},{"nctId":"NCT02092467","phase":"PHASE4","title":"Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-03-14","conditions":"Arthritis, Rheumatoid","enrollment":4372},{"nctId":"NCT02100696","phase":"PHASE3","title":"A Study of the Efficacy and Safety of Etrolizumab in Participants With Ulcerative Colitis Who Have Been Previously Exposed to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-05-21","conditions":"Ulcerative Colitis","enrollment":609},{"nctId":"NCT02171429","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-14","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT02163759","phase":"PHASE3","title":"A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-11-04","conditions":"Ulcerative Colitis","enrollment":358},{"nctId":"NCT04973787","phase":"","title":"The Role of Microbiome on Biological Therapy Efficacy in axSpA and RA","status":"UNKNOWN","sponsor":"Universidade Nova de Lisboa","startDate":"2020-08-01","conditions":"Axial Spondyloarthritis, Arthritis, Rheumatoid","enrollment":90},{"nctId":"NCT04953871","phase":"PHASE4","title":"Enthesitis Assessment Before and After Anti-Tumor Necrosis Factor Treatment in Spondyloarthritis","status":"COMPLETED","sponsor":"Gunay ER","startDate":"2017-01","conditions":"Spondyloarthritis, Enthesitis, Anti-Tumor Necrosis Factor Drugs","enrollment":31},{"nctId":"NCT02015520","phase":"PHASE2","title":"Phase IIB Dose Ranging Study in Subjects With Moderate to Severe Rheumatoid Arthritis","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2012-06","conditions":"Rheumatoid Arthritis","enrollment":143},{"nctId":"NCT03561649","phase":"NA","title":"Prediction of Treatment Response at 6 Months by Combinatorial Analysis of Serum Biomarkers in Biotherapy Naive SpA","status":"COMPLETED","sponsor":"University Hospital, Grenoble","startDate":"2018-06-14","conditions":"Spondylitis, Ankylosing","enrollment":50},{"nctId":"NCT01764321","phase":"","title":"Noninterventional Examination of Subcutaneous (sc) Tumor Necrosis Factor (TNF) Inhibitors","status":"COMPLETED","sponsor":"UCB Pharma SA","startDate":"2012-12","conditions":"Rheumatoid Arthritis","enrollment":1723},{"nctId":"NCT03802214","phase":"","title":"Ulcerative Colitis - Vedolizumab- With/Without Prior Exposure to Anti-TNF（Tumor Necrosis Factor）Therapy","status":"TERMINATED","sponsor":"Stanford University","startDate":"2020-10-29","conditions":"Ulcerative Colitis","enrollment":1},{"nctId":"NCT01548768","phase":"PHASE4","title":"RHYTHM (Formerly Escape II Myocardium)","status":"COMPLETED","sponsor":"Columbia University","startDate":"2011-10-10","conditions":"Rheumatoid Arthritis","enrollment":149}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":366,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"TNF antagonist","genericName":"TNF antagonist","companyName":"Brigham and Women's Hospital","companyId":"brigham-and-women-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TNF antagonists, such as Adalimumab, are used to treat conditions including Crohn's Disease, Polyarticular Course Juvenile Idiopathic Arthritis, Rheumatoid Arthritis, and Reactive Arthritis. They work by suppressing the inflammatory response caused by tumor necrosis factor (TNF), a key component of the body's inflammatory response.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}